Targeting IL-4 for the Treatment of Atopic Dermatitis.

IF 6.2 Q1 IMMUNOLOGY

ImmunoTargets and Therapy Pub Date : 2020-09-29 eCollection Date: 2020-01-01 DOI:10.2147/ITT.S260370

Andrea Chiricozzi, Martina Maurelli, Ketty Peris, Giampiero Girolomoni

引用次数: 41

Abstract

Atopic dermatitis (AD) is an immune-mediated inflammatory skin disease characterized by a predominant type 2 immune response. Type 2 immunity is driven by multiple cytokines, including interleukin (IL)‑4 and IL-13 that are considered central to AD pathogenesis and key therapeutic targets. The dual inhibition of these two cytokines or the selective inhibition of IL-13 proved elevated efficacy in treating AD, whereas the selective inhibition of IL-4 has been poorly investigated as IL-4 inhibiting agents did not show any advance in clinical development programs. This review describes the pathogenic role of IL-4 in AD and briefly resumes the main features of compounds selectively blocking IL-4.

查看原文本刊更多论文

靶向IL-4治疗特应性皮炎。

特应性皮炎(AD)是一种以2型免疫应答为主的免疫介导的炎症性皮肤病。2型免疫由多种细胞因子驱动，包括白细胞介素(IL) - 4和IL-13，它们被认为是AD发病机制和关键治疗靶点的核心。这两种细胞因子的双重抑制或选择性抑制IL-13证明了治疗AD的有效性，而选择性抑制IL-4的研究很少，因为IL-4抑制剂在临床开发计划中没有显示出任何进展。本文综述了IL-4在AD中的致病作用，并简要介绍了选择性阻断IL-4的化合物的主要特点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ImmunoTargets and Therapy IMMUNOLOGY-

CiteScore

16.50

自引率

0.00%

发文量

审稿时长

16 weeks

期刊介绍： Immuno Targets and Therapy is an international, peer-reviewed open access journal focusing on the immunological basis of diseases, potential targets for immune based therapy and treatment protocols employed to improve patient management. Basic immunology and physiology of the immune system in health, and disease will be also covered.In addition, the journal will focus on the impact of management programs and new therapeutic agents and protocols on patient perspectives such as quality of life, adherence and satisfaction.